Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
easyJet Agrees in Principle to £5.23 Billion Castlelake Takeover Offer 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Meta Stock Jumps as AI Cloud Expansion Challenges AWS, Microsoft, and Google 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
